Protalix BioTherapeutics, Inc.
PLXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 13, 2026 | Raymond James | Tiago Fauth | $6.00(+129%) | $2.62 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 9, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 19, 2026 |
| HC Wainwright & Co. | maintain | Buy | Nov 21, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 3, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 14, 2023 |
| HC Wainwright & Co. | maintain | Buy | Oct 31, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jun 8, 2020 |
| Rodman & Renshaw | maintain | Buy | Apr 17, 2017 |
| Jefferies | maintain | Buy | Sep 6, 2016 |
| Rodman & Renshaw | maintain | Buy | Apr 4, 2016 |
| Jefferies | maintain | Buy | Apr 23, 2015 |
| JP Morgan | maintain | Overweight | May 13, 2014 |
| Jefferies | maintain | Hold | May 12, 2014 |
| RF Lafferty | maintain | Buy | Jan 23, 2014 |
| JP Morgan | maintain | Overweight | Oct 21, 2013 |
| Jefferies | maintain | Hold | Nov 9, 2012 |
| Aegis Capital | maintain | Hold | Jul 16, 2012 |
| Wells Fargo | downgrade | Outperform →Perform | Jun 25, 2012 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $0.05 | $-0.01 | $19.9M | $12.9M |
| May 13, 2026 | $0.22 | $-0.01 | $33.8M | $11.5M |
| Mar 18, 2026 | $-0.07 | $0.01 | $9.1M | $18.3M |
| Nov 13, 2025 | $0.03 | $0.06 | $17.9M | $14.2M |
| Aug 14, 2025 | $0.00 | $0.03 | $15.7M | $13.5M |
| May 9, 2025 | $-0.05 | $0.08 | $10.1M | $23.1M |
| Mar 17, 2025 | $0.09 | $0.07 | $18.2M | $21.6M |
| Nov 14, 2024 | $0.03 | $0.06 | $18.0M | $18.2M |
News
Company to host conference call and webcast at 8:00 a.m. ET CARMIEL, Israel, Nov. 3, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended September 30, 2026 and provide a business update on November 10, 2026.
Protalix BioTherapeutics, Inc. (PLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
CARMIEL, Israel, Sept. 8, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that Gilad Mamlok, Senior Vice President and Chief Financial Officer, is scheduled to participate in the following two upcoming investor conferences in New York City, New York: H.C.
Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript
Company to host conference call and webcast today at 8:00 a.m. EDT Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4 million from the second quarter of 2025, driven primarily by sales of Elfabrio® Total revenue climbed to $53.6 million, year to date, from $25.8 million for the same period in 2025, which includes the previously reported $25.0 million Chiesi milestone payment Year-to-date, the Company achieved profitability with a net income of $22.1 mil…